- Home
- ENGN vs ADCT Comparison
ENGN vs ADCT Comparison
Compare ENGN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- ADCT
- Stock Information
- Founded
- ENGN 1999
- ADCT 2011
- Country
- ENGN Canada
- ADCT Switzerland
- Employees
- ENGN N/A
- ADCT N/A
- Industry
- ENGN
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- ADCT Health Care
- Exchange
- ENGN Nasdaq
- ADCT Nasdaq
- Market Cap
- ENGN 321.5M
- ADCT 398.2M
- IPO Year
- ENGN N/A
- ADCT 2020
- Fundamental
- Price
- ENGN $6.52
- ADCT $3.26
- Analyst Decision
- ENGN Buy
- ADCT Strong Buy
- Analyst Count
- ENGN 8
- ADCT 6
- Target Price
- ENGN $21.50
- ADCT $7.80
- AVG Volume (30 Days)
- ENGN 225.5K
- ADCT 545.2K
- Earning Date
- ENGN 09-11-2025
- ADCT 11-06-2025
- Dividend Yield
- ENGN N/A
- ADCT N/A
- EPS Growth
- ENGN N/A
- ADCT N/A
- EPS
- ENGN N/A
- ADCT N/A
- Revenue
- ENGN N/A
- ADCT $77,246,000.00
- Revenue This Year
- ENGN N/A
- ADCT $13.10
- Revenue Next Year
- ENGN N/A
- ADCT $6.23
- P/E Ratio
- ENGN N/A
- ADCT N/A
- Revenue Growth
- ENGN N/A
- ADCT 15.73
- 52 Week Low
- ENGN $2.65
- ADCT $1.05
- 52 Week High
- ENGN $11.00
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- ENGN 77.94
- ADCT 52.13
- Support Level
- ENGN $5.52
- ADCT $3.15
- Resistance Level
- ENGN $6.54
- ADCT $3.38
- Average True Range (ATR)
- ENGN 0.55
- ADCT 0.17
- MACD
- ENGN 0.11
- ADCT -0.01
- Stochastic Oscillator
- ENGN 99.17
- ADCT 39.45
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).